ProMIS Neurosciences Adds Brain-Targeting Technology to Advance Next-Generation Alzheimer’s Antibody
Key Points
- ProMIS Neurosciences has licensed Ossianix's TXP1 transferrin receptor shuttle to improve antibody delivery across the blood-brain barrier, initially for its PMN310 Alzheimer's candidate.
- Preclinical studies showed TXP1 increased brain delivery of a therapeutic antibody by more than 65-fold, with no detectable accumulation in several peripheral organs.
- The agreement includes options for PMN442 in Parkinson's disease and PMN267 in ALS, plus an upfront payment, milestones and royalties for Ossianix.
ProMIS Neurosciences has secured licensing rights to a next-generation brain delivery technology from Ossianix, aiming to improve antibody transport across the blood-brain barrier and expand the development potential of its neurodegenerative disease pipeline. Under the agreement, ProMIS will gain access to Ossianix’s TXP1 technology, a transferrin receptor 1 (TfR1)-targeting shuttle designed to increase the delivery of therapeutic antibodies to the brain. The initial focus will be on combining TXP1 with PMN310, ProMIS’s lead antibody candidate for Alzheimer’s disease, with additional options to incorporate the technology into programs targeting Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Preclinical studies conducted by Ossianix, including research in non-human primates, demonstrated that TXP1 increased brain delivery of a therapeutic antibody by more than 65-fold. The company also reported that the technology did not produce detectable accumulation in several peripheral organs, including the liver, spleen, lungs, kidneys, bone marrow, heart and muscle.
TXP1 is built around a deimmunized, single-domain VNAR antibody scaffold, which is considerably smaller than conventional antibodies. According to the companies, the technology binds to a distinct TfR1 epitope without competing with transferrin and has demonstrated prolonged exposure in the brain. Preclinical testing also indicated minimal effects on reticulocyte levels, an issue reported with some other TfR1-based delivery approaches.
For ProMIS, the license could provide a pathway to develop a next-generation version of PMN310 with improved brain penetration and potentially more convenient dosing. The company is evaluating opportunities to combine the shuttle with its existing antibody program to support a subcutaneous formulation and potentially lower manufacturing costs.
“Our ongoing efforts with PMN310 are unaffected by this agreement, and we remain committed to advancing it as an intravenous and subcutaneous product, subject to upcoming data,” says Neil Warma, President and CEO of ProMIS Neurosciences. He describes TXP1 as a promising addition to the company’s pipeline and said the combination of selective antibodies and enhanced brain delivery could support future product development. And, he adds that the technology could also create opportunities to extend the company’s approach to other neurodegenerative conditions.
Beyond PMN310, the agreement gives ProMIS options to apply TXP1 to two additional antibody candidates. These include PMN442, which targets alpha-synuclein, a protein associated with Parkinson’s disease and dementia with Lewy bodies, and PMN267, which targets TDP-43, a protein implicated in ALS and frontotemporal dementia.
The licensing arrangement includes an upfront payment to Ossianix, along with eligibility for development, regulatory and commercial milestone payments and royalties on worldwide net sales.
ProMIS expects to cover its near-term financial commitments under the agreement using existing cash resources. The company also stated that the transaction is not expected to affect its previously announced cash runway through 2027.
The collaboration adds another potential strategy for addressing one of the central challenges in neurological drug development: delivering sufficient quantities of therapeutic antibodies across the blood-brain barrier while maintaining selectivity for disease-associated targets.
Find more information at www.promisneurosciences.com.
Total Page Views: 1

















